Introduction: Recent studies have demonstrated the role of osteocalcin in energy metabolism regulation having a connection between this and bone metabolism. According to this, anti-osteoporotic drugs may exert different effects on energy metabolism. Thereby, our aim is to evaluate the effects of antiresorptive (Denosumab) and osteoanabolic (Teriparatide) drugs that reduce or increase respectively osteocalcin (OC) levels, on energy and bone metabolism by assessing of undercarboxilated osteocalcin (ucOC), myostatin and sclerostin levels.
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Serum sclerostin levels were increased but not significantly in Denosumab group at first week, first and third month (2.9%, 10.6%, 8.5% respectively) and decreased in Teriparatide group (0.7%, 3.8%, 1.9%, respectively, p>0.05); However, there were significant differences between groups at first month (p=0.03). Bone markers were significantly decreased in Denosumab group (p<0.01) and increased in Teriparatide group (p<0.05); significant differences between groups (p<0.05). PTH levels were significantly higher at first and third month in Denosumab group (65%, 21.5%, respectively, p<0.05) with significative differences between groups (p<0.001).
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